Zelluna ASA Logo

Zelluna ASA

Develops off-the-shelf, TCR-guided NK cell immunotherapies for solid cancers.

ULTI | OL

Overview

Corporate Details

ISIN(s):
NO0010851603
LEI:
254900B4VALJZR9TL744
Country:
Norway
Address:
Ullernchausseen 64, 0379 Oslo

Description

Zelluna ASA is a cell therapy company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company's proprietary TCR-NK platform is designed to combine the high-precision targeting of TCRs with the potent, innate anti-tumor activity of NK cells. This approach aims to overcome the challenges associated with treating solid tumors. Zelluna is focused on creating a new generation of allogeneic, "off-the-shelf" cell therapies. The mission is to deliver transformative and potentially curative treatments for patients with advanced solid cancers, addressing a significant unmet medical need.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-12 13:02
Zelluna Completes First GMP Batch of ZI-MA4-1, a Novel TCR-NK Cell Therapy, to …
English 4.7 KB
2025-12-09 09:36
Zelluna ASA: Cancellation of subsequent repair offering
English 1.8 KB
2025-12-09 08:22
Financial calendar
English 749 bytes
2025-12-08 18:36
Zelluna ASA - Mandatory notification of trade - Attachment: PDMR attachment.pdf
English 102.0 KB
2025-12-08 18:36
Zelluna ASA - Mandatory notification of trade
English 579 bytes
2025-12-08 13:52
Zelluna ASA: New share capital registered
English 2.4 KB
2025-11-28 07:50
Zelluna ASA Announces Appointment of Geir Christian Melen as New Chief Financia…
English 4.2 KB
2025-11-27 08:35
Zelluna ASA: Disclosure of large shareholding
English 1.8 KB
2025-11-25 16:05
Zelluna ASA: Disclosure of large shareholding
English 1.4 KB
2025-11-25 12:09
ZELLUNA ASA: DISCLOSURE OF LARGE SHAREHOLDING
English 1.5 KB
2025-11-25 11:32
Zelluna ASA - Extraordinary General Meeting held on November 25, 2025 - Attachm…
English 325.0 KB
2025-11-25 11:32
Zelluna ASA - Extraordinary General Meeting held on November 25, 2025 - Attachm…
Norwegian 258.2 KB
2025-11-25 11:32
Zelluna ASA - Extraordinary General Meeting held on November 25, 2025
English 1.5 KB
2025-11-04 13:04
Zelluna ASA: Notice of extraordinary general meeting on 25 November 2025 - Atta…
Norwegian 1014.6 KB
2025-11-04 13:04
Zelluna ASA: Notice of extraordinary general meeting on 25 November 2025
English 1.4 KB

Automate Your Workflow. Get a real-time feed of all Zelluna ASA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Zelluna ASA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Zelluna ASA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Celltrion, Inc. Logo
Biopharmaceutical firm developing biosimilars for autoimmune diseases and oncology.
South Korea
068270
Celltrion Pharm Inc. Logo
Manufactures and supplies chemical pharmaceuticals and biosimilar products.
South Korea
068760
Develops and manufactures medical devices, tissue grafts, and advanced biologics.
South Korea
049180
Celon Pharma S.A. Logo
An integrated pharmaceutical company researching and manufacturing modern drugs.
Poland
CLN
Celularity Inc Logo
Develops allogeneic cell therapies and biomaterials from the human placenta.
United States of America
CELU
Centessa Pharmaceuticals plc Logo
Clinical-stage pharmaceutical company developing medicines for unmet medical needs.
United States of America
CNTA
Century Therapeutics, Inc. Logo
Develops iPSC-derived allogeneic cell therapies for cancer and autoimmune diseases.
United States of America
IPSC
Cereno Scientific AB Logo
Clinical-stage biotech developing drugs for rare cardiovascular & pulmonary diseases.
Sweden
CRNO
CERO THERAPEUTICS HOLDINGS, INC. Logo
Immunotherapy company developing engineered T cell therapeutics for cancer treatment.
United States of America
CERO
CERUS CORP Logo
Develops pathogen inactivation technology to reduce transfusion-transmitted infections.
United States of America
CERS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.